Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Worried about Q2 results, think six (6) market factors…

August 5, 2019 9:55am

Volatility, algorithms, sustainability … but, geopolitical ssues are "trumping" the news

Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019?

Why spend time finding sector news and analytics … it’s all right here!

News has become "something" sold into

Learn why pricing is stumbling and what the mumbling means … review daily indicators, factors and trend lines, advance/decline lines, pre-open indicator results and volatility and of the percentage (%) count of the Advance/Decline (A/D) line.

RMi is the only source of actionable intelligence for the stem, cell and gene therapies companies of the regenerative medicine universe.

You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s exclusive listing of “our” universe’s stocks and their potential for gains and losses; but exclusivity is now here. Access to RegMed Investors’ targeted content is by subscription.

For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:

http://www.regmedinvestors.com/create-account

Never leave an investor uninformed

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 33 min ago
RegMed Investors (RMi) Closing Bell: hammered

15 hours 24 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.